Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 32Breast Neoplasms 18Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Sarcoma 6Prostatic Neoplasms 6Fanconi Anemia, Complementation Group D1 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Recurrence 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Mesothelioma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Advanced Solid Tumours 2Advanced Solid Tumors 2Wilms Tumor 1

Interventions

tetracarboxyphenylporphine 1testosterone enanthate 1testosterone 17 beta-cypionate 1olaparib 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castration-Resistant Prostate Carcinoma × olaparib × Clear all
NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

Phase 2 Completed
36 enrolled 14 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡